财务迷局撕开早筛赛道假面:诺辉健康德勤拒签财报,1.92亿赔偿先例难救6次估值腰斩的投资者

财鲸眼
Oct 16, 2025

一场始于 7.65 亿元与 7695 万元的销售数据争议,将曾经的 “癌症早筛第一股” 拖入退市深渊,18 个月停牌期背后,是投资者权益与行业信任的双重考验。26.66 港元上市到 14.14 港元停牌,9 倍差额引信任危机2021 年 2 月,成立 6 年的诺辉健康在港交所敲钟,以 26.66 港元发行价成为 “中国癌症早筛第一股”(股票代码6606.HK),其核心产品矩阵曾被视作行业标杆 ——...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10